KPC Pharmaceuticals Inc (600422) - Total Liabilities
Based on the latest financial reports, KPC Pharmaceuticals Inc (600422) has total liabilities worth CN¥5.15 Billion CNY (≈ $753.67 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 600422 cash flow metrics to assess how effectively this company generates cash.
KPC Pharmaceuticals Inc - Total Liabilities Trend (1997–2024)
This chart illustrates how KPC Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check 600422 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
KPC Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of KPC Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hana Materials Inc
KQ:166090
|
Korea | ₩207.70 Billion |
|
Yangzhou Seashine New Materials Co
SHE:300885
|
China | CN¥60.63 Million |
|
GRIPM Advanced Materials Co. Ltd. A
SHG:688456
|
China | CN¥586.27 Million |
|
AirAsia X Bhd
KLSE:5238
|
Malaysia | RM2.84 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩231.24 Billion |
|
Trican Well Service Ltd.
TO:TCW
|
Canada | CA$317.87 Million |
|
Electra Real Estate Ltd
TA:ELCRE
|
Israel | ILA1.95 Billion |
|
GuangDong Leary New Material Technology Co. Ltd. A
SHG:688683
|
China | CN¥652.65 Million |
Liability Composition Analysis (1997–2024)
This chart breaks down KPC Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KPC Pharmaceuticals Inc (600422) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how KPC Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for KPC Pharmaceuticals Inc (1997–2024)
The table below shows the annual total liabilities of KPC Pharmaceuticals Inc from 1997 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥5.87 Billion ≈ $858.25 Million |
+43.44% |
| 2023-12-31 | CN¥4.09 Billion ≈ $598.32 Million |
-4.68% |
| 2022-12-31 | CN¥4.29 Billion ≈ $627.68 Million |
+8.52% |
| 2021-12-31 | CN¥3.95 Billion ≈ $578.39 Million |
+12.31% |
| 2020-12-31 | CN¥3.52 Billion ≈ $515.01 Million |
+13.50% |
| 2019-12-31 | CN¥3.10 Billion ≈ $453.74 Million |
+5.36% |
| 2018-12-31 | CN¥2.94 Billion ≈ $430.67 Million |
+14.76% |
| 2017-12-31 | CN¥2.56 Billion ≈ $375.26 Million |
+43.25% |
| 2016-12-31 | CN¥1.79 Billion ≈ $261.97 Million |
+11.03% |
| 2015-12-31 | CN¥1.61 Billion ≈ $235.95 Million |
+65.48% |
| 2014-12-31 | CN¥974.40 Million ≈ $142.59 Million |
-3.20% |
| 2013-12-31 | CN¥1.01 Billion ≈ $147.31 Million |
-8.07% |
| 2012-12-31 | CN¥1.10 Billion ≈ $160.24 Million |
+53.72% |
| 2011-12-31 | CN¥712.37 Million ≈ $104.24 Million |
+19.56% |
| 2010-12-31 | CN¥595.84 Million ≈ $87.19 Million |
+17.80% |
| 2009-12-31 | CN¥505.79 Million ≈ $74.01 Million |
+3.97% |
| 2008-12-31 | CN¥486.48 Million ≈ $71.19 Million |
-12.34% |
| 2007-12-31 | CN¥554.98 Million ≈ $81.21 Million |
+1.94% |
| 2006-12-31 | CN¥544.44 Million ≈ $79.67 Million |
-16.28% |
| 2005-12-31 | CN¥650.31 Million ≈ $95.16 Million |
+44.92% |
| 2004-12-31 | CN¥448.75 Million ≈ $65.67 Million |
+56.49% |
| 2003-12-31 | CN¥286.76 Million ≈ $41.96 Million |
+49.26% |
| 2002-12-31 | CN¥192.11 Million ≈ $28.11 Million |
-5.94% |
| 2001-12-31 | CN¥204.24 Million ≈ $29.89 Million |
-15.31% |
| 2000-12-31 | CN¥241.15 Million ≈ $35.29 Million |
-18.03% |
| 1999-12-31 | CN¥294.19 Million ≈ $43.05 Million |
+10.99% |
| 1998-12-31 | CN¥265.06 Million ≈ $38.79 Million |
+53.98% |
| 1997-12-31 | CN¥172.13 Million ≈ $25.19 Million |
-- |
About KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotics,… Read more